Nanosonics (ASX:NAN): FY26 Results, CORIS Launch Plans and FY27 Guidance

Aditi Sarkar

26 October 2026 03:57 PM AEDT

Nanosonics (ASX:NAN): FY26 Results, CORIS Launch Plans and FY27 Guidance

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Nanosonics (ASX:NAN) increased FY26 revenue by 3% YoY to AUD 203.9mn.
Global trophon installed base reached 39,230 devices after 4,230 annual placements.
FY26 EBIT decreased 10% YoY to AUD 16.0mn; year-end cash was AUD 155.2mn.
The company guided FY27 constant-currency revenue to AUD 220mn–228mn.

Nanosonics Limited develops infection-prevention technologies for medical device reprocessing, including its trophon ultrasound-probe disinfection systems and CORIS endoscope-reprocessing platform. On 26 October 2026, Nanosonics (ASX:NAN) was quoted at AUD 3.055, up 0.49% for the session. Its latest annual results outlined higher device placements, increased revenue, a decline in reported EBIT and preparations for commercial introduction of CORIS during FY27.

Company Business

Nanosonics (ASX:NAN) supplies automated high-level disinfection equipment, related consumables, service and digital support to healthcare facilities. Its trophon business addresses reprocessing of ultrasound probes; capital equipment placements create an installed base that subsequently uses consumables and service offerings. The company sells internationally, with North America accounting for most of its annual trophon placements.

The next-generation trophon3 device and trophon2 Plus software package support upgrades within that installed base. CORIS is a separate technology platform designed for reprocessing flexible endoscopes, with controlled market release activities preceding wider commercial availability. The expansion requires product registration, manufacturing capacity, distribution arrangements and customer adoption.

Recent Development

In August 2026, Nanosonics (ASX:NAN) reported 4,230 trophon placements for FY26, up 9% YoY. Its cumulative global installed base increased 6% to 39,230 devices, including 2,230 additions. North American placements reached 3,880, up 13% YoY, while regional upgrade units increased 32% YoY to 1,980. Adoption of trophon3 and trophon2 Plus accelerated during the second half.

The company reported that CORIS controlled market releases were under way across several jurisdictions. Regulatory milestones included clearances in Australia, Europe and the United Kingdom, as well as an initial US FDA 510(k) clearance covering specified indications. It planned commercial launches in the United Kingdom, Ireland and Australia in H1FY27, followed by the United States. During FY26, the company completed a AUD 20mn share buyback and subsequently announced a new on-market program of up to AUD 40mn for FY27.

Financial Performance and Sector Context

Nanosonics (ASX:NAN) recorded FY26 revenue of AUD 203.9mn, compared with AUD 198.6mn in FY25, representing 3% YoY growth. At constant currency, revenue was AUD 211.5mn, up 6% YoY. Capital revenue rose 4% YoY to AUD 54.7mn and recurring revenue increased 2% YoY to AUD 149.2mn. Currency movements affected reported growth because a significant proportion of sales is denominated in USD.

FY26 EBIT decreased 10% YoY to AUD 16.0mn from AUD 17.8mn, while operating expenses rose 2% YoY to AUD 141.4mn. Gross margin moderated to 76.9% from 78.2%. The trophon-only business generated EBIT of AUD 50.6mn, up 5% YoY, before costs associated with the CORIS platform. Cash and cash equivalents stood at AUD 155.2mn on 30 June 2026, and the company reported no debt.

For FY27, the company guided constant-currency revenue of AUD 220mn–228mn, equivalent to 8%–12% growth against FY26 on that basis. Its gross-margin guidance was 74%–76%, with operating expenses of AUD 156mn–163mn. It also expected initial CORIS revenue in the low single-digit millions of Australian dollars. These ranges incorporate planned commercialisation spending and assumptions about tariffs and foreign exchange.

Risks to Consider

Nanosonics (ASX:NAN) faces currency translation exposure, tariff and freight costs, and execution risks associated with launching a new reprocessing system. CORIS expenditure may precede meaningful revenue, while adoption depends on clinical workflows, available indications, procurement decisions and regulatory progress. The timing of product upgrades and the mix of equipment, consumables and services can also affect margins.

What to Watch Next

Relevant milestones for Nanosonics (ASX:NAN) include the intended H1FY27 CORIS launches, subsequent US rollout preparations, additional regulatory submissions and early customer adoption. Further disclosures on trophon placements, recurring revenue, gross margin and expenditure will indicate how the existing business and new platform contribute to FY27 results. The company has also scheduled its annual general meeting for November 2026.

Key Insights

Nanosonics (ASX:NAN) ended FY26 with a larger trophon installed base and higher revenue, although reported EBIT and gross margin declined. Its cash position provides resources for CORIS commercialisation and the announced capital-management program. Execution of the launch timetable, operating costs, recurring sales and currency effects remain central measurable developments.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.